Spruce Biosciences to Present at Upcoming Investor Conferences in March

Mon, 02 Mar 2026 16:05:00 -0500

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March.

Leerink Global Healthcare Conference
Date and Time: March 9, 2026, at 11:20 a.m. ET
Format: Fireside chat and 1x1 meetings
Location: Miami, FL

The Citizens Life Sciences Conference
Date and Time: March 10, 2026, at 12:30 p.m. ET
Spruce Biosciences to Present at Upcoming Investor Conferences in March

Mon, 02 Mar 2026 16:05:00 -0500

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March.
- Leerink Global Healthcare Conference
  Date and Time: March 9, 2026, at 11:20 a.m. ET
  Format: Fireside chat and 1x1 meetings
  Location: Miami, FL
- The Citizens Life Sciences Conference
  Date and Time: March 10, 2026, at 12:30 p.m. ET
  Spruce Biosciences to Present at Upcoming Investor Conferences in March
  
  Mon, 02 Mar 2026 16:05:00 -0500
  
  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March.
  - Leerink Global Healthcare Conference
    Date and Time: March 9, 2026, at 11:20 a.m. ET
    Format: Fireside chat and 1x1 meetings
    Location: Miami, FL
  - The Citizens Life Sciences Conference
    Date and Time: March 10, 2026, at 12:30 p.m. ET
    
    Spruce Biosciences to Present at Upcoming Investor Conferences in March
    
    Mon, 02 Mar 2026 16:05:00 -0500
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March.
    
    Leerink Global Healthcare Conference
    Date and Time: March 9, 2026, at 11:20 a.m. ET
    Format: Fireside chat and 1x1 meetings
    Location: Miami, FL
    
    The Citizens Life Sciences Conference
    Date and Time: March 10, 2026, at 12:30 p.m. ET
    
    Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
    
    Tue, 24 Feb 2026 16:47:00 -0500
    si-local-file:///var/storage/secattach/20260224/26052579.html
    
    Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
    
    Tue, 24 Feb 2026 16:47:00 -0500
    si-local-file:///var/storage/secattach/20260224/26052579.html
    
    Spruce Biosciences, Inc. (SPRB) PT Lowered to $200 at H.C. Wainwright
    
    Thu, 19 Feb 2026 06:49:32 -0500
    H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $200.00 (from $220.00) while maintaining a Buy rating.
    
    Form SCHEDULE 13D/A SPRUCE BIOSCIENCES, INC. Filed by: Carlyle Group Inc.
    
    Wed, 18 Feb 2026 17:27:00 -0500
    si-local-file:///var/storage/secattach/20260218/26023746.html
    
    Form SCHEDULE 13D/A SPRUCE BIOSCIENCES, INC. Filed by: Carlyle Group Inc.
    
    Wed, 18 Feb 2026 17:27:00 -0500
    si-local-file:///var/storage/secattach/20260218/26023746.html
    
    Spruce Biosciences, Inc. (SPRB) PT Lowered to $180 at Citizens
    
    Wed, 18 Feb 2026 17:10:08 -0500
    Citizens analyst Jonathan Wolleben lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $180.00 (from $259.00) while maintaining a Market Outperform rating.
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    
    Wed, 18 Feb 2026 07:00:00 -0500
    
    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval
    BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement
    
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming
    
    Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: ADAR1 Capital Management, LLC
    
    Tue, 17 Feb 2026 20:17:00 -0500
    si-local-file:///var/storage/secattach/20260217/26016123.html
    
    Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: ADAR1 Capital Management, LLC
    
    Tue, 17 Feb 2026 20:17:00 -0500
    si-local-file:///var/storage/secattach/20260217/26016123.html
    
    Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: Alyeska Investment Group, L.P.
    
    Tue, 17 Feb 2026 16:53:00 -0500
    si-local-file:///var/storage/secattach/20260217/26014619.html

StreetInsider.com News Articles

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Spruce Biosciences, Inc. (SPRB) PT Lowered to $200 at H.C. Wainwright

Form SCHEDULE 13D/A SPRUCE BIOSCIENCES, INC. Filed by: Carlyle Group Inc.

Form SCHEDULE 13D/A SPRUCE BIOSCIENCES, INC. Filed by: Carlyle Group Inc.

Spruce Biosciences, Inc. (SPRB) PT Lowered to $180 at Citizens

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: ADAR1 Capital Management, LLC

Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: ADAR1 Capital Management, LLC

Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: Alyeska Investment Group, L.P.